The incidence and prognostic factors for chronic graftversus-host disease (cGVHD) were evaluated for 255 Japanese patients who survived more than 100 days after bone marrow transplantation, and of whom 119 (47%) developed cGVHD. Prior acute GVHD (grade 2-4) and use of an unrelated donor were significantly associated with the onset of cGVHD. Presence of cGVHD did not have an impact on mortality (hazard ratio (HR) ¼ 0.89; 95% confidence interval (CI), 0.59-1.3). Three factors at diagnosis were associated with cGVHD-specific survival: presence of infection (HR ¼ 4.1; 95% CI, 1.6-10.3), continuing use of corticosteroids at the onset of cGVHD (HR ¼ 3.9; 95% CI, 1.7-9.1), and a Karnofsky performance score o80 (HR ¼ 4.7; 95% CI, 2.0-11.3). The probability of cGVHD-specific survival at 4 years was 79% (95% CI, 70-86%). The severity and death rate of Japanese patients with cGVHD was lower than those for populations in Western countries, which might be the result of greater genetic homogeneity of Japanese ethnics. Our patients could not be accurately classified when the proposed prognostic models from Western countries were used, thus indicating the need for a different model to identify high-risk patients.
Introduction
Chronic graft-versus-host disease (cGVHD) is an important complication of allogeneic hematopoietic stem cell transplantation (HSCT) with a reported incidence from 30 to 70%. 1, 2 To date, a variety of factors have been found to be associated with the development of cGVHD (reviewed by Higman and Vogelsang 3 ). The most important factor is the presence of prior aGVHD, which has been repeatedly identified in several studies. [2] [3] [4] [5] [6] [7] Other factors include older age, diagnosis of chronic myelogenous leukemia, female donor to male recipient, and the use of an unrelated donor. 2, 4, 6, 7 A recent meta-analysis confirmed that use of peripheral blood stem cells significantly increases the risk of cGVHD. 8 Chronic GVHD can be classified according to the extent of disease with the most commonly used grading system dividing cGVHD into limited or extensive disease. This system was proposed in 1980 based on the clinicopathologic findings of 20 patients. 9 However, the majority of patients come under the extensive cGVHD category, which is characterized by highly heterogeneous manifestations. For this reason, this grading system, although highly reproducible and useful for clinical decision making as to whether to initiate treatment, provides only limited information on the prognosis of patients. 10, 11 Several clinical and biologic features have been identified as prognostically significant in previous studies of cGVHD, including categorization as extensive cGVHD, 9, 12 Karnofsky performance status (KPS), 12 thrombocytopenia (o100 000 mm 3 ), 12, 13 progressive-type onset of cGVHD, 14 lichenoid histology, 14 and elevated bilirubin. 14 According to recently introduced new clinical grading systems for cGVHD, 10, 11 thrombocytopenia, progressive-type onset, and extensive skin GVHD, involving more than 50% of body surface area at the diagnosis of cGVHD, are independent risk factors affecting relapse-free survival. 10 One of these systems uses a novel scoring method based on the results of 151 patients 10 and the validity and significance of this system were confirmed in 1105 patients from multiple institutions. 15 Lee et al. 11 identified high KPS (X80%) and oral involvement as favorable prognostic signs, and cutaneous involvement, diarrhea, and weight loss as unfavorable prognostic factors.
Because of the historically determined genetic homogeneity of the Japanese population 16 compared to those in Western countries, Japanese patients who receive allogeneic HSCT show a lower incidence of acute GVHD. [17] [18] [19] This finding prompted us to analyze a series of Japanese patients in an attempt to identify the incidence and risk factors of cGVHD as well as the prognostic factors for patients who developed cGVHD in the Japanese context.
Patients and methods

Patients
In the 5-year period from January 1995 to December 1999, a total of 400 patients with allogeneic HSCT were treated consecutively at eight centers belonging to the Nagoya Blood and Marrow Transplantation Group (NBMTG). This is a collaborative group consisting of 22 adult and three child HSCT centers. Eight centers of NBMTG which perform allogeneic transplants participated in this study. Of the 400 patients, 301 received bone marrow transplantation (BMT) from either an HLA genotypically matched relative or from HLA A, B, DR genotypically matched unrelated donors. Only patients who underwent BMT were included in this study, and those who received a peripheral blood stem cell transplant or who underwent two or more HSCT procedures were not. The study population comprised 255 patients who survived longer than 100 days post transplant, while patients who developed GVHD after donor leukocyte infusion (n ¼ 2) or who decided themselves to abandon immunosuppressive agents (n ¼ 1) were not included.
Diagnosis and staging of cGVHD Diagnosis of cGVHD was based on clinical criteria of skin, oral and other affected sites as previously described. 9, 20 The diagnosis of cGVHD was confirmed by histologic studies of skin, oral, or other affected sites in 60 of 110 patients (54.6%) who were clinically diagnosed. Established criteria were used for the histologic diagnosis. 9, 21 Staging of cGVHD was originally performed by institutional physicians, and was reviewed on the basis of these physicians' data sheets by three independent hematologists (YA, RS and KY) using the most commonly used criteria. 9 The stage in agreement was used for the analyses.
Analysis of demographic variables for risk factors of extensive cGVHD
Patient age, sex, diagnosis of primary disease, disease status at transplant, donor type, preparative regimen, GVHD prophylaxis, and prior aGVHD grade were examined for risk factors of cGVHD.
Demographics, clinical, and laboratory variables analyzed for prognostic factors for those who developed cGVHD The following variables documented at the time of diagnosis of cGVHD were used for our study: age, sex, donor type, donor/recipient sex matching, pretransplant disease status, preparative regimen, GVHD prophylaxis, prior occurrence and severity of aGVHD, positive cytomegalovirus status (donor and/or recipient), mode of presentation of cGVHD, serum alkaline phosphatase and total bilirubin, peripheral blood platelet count, absolute serum immunoglobulin level, blood eosinophil percentage, and use of corticosteroids before initiation of treatment of cGVHD. The extent and severity of cGVHD in the affected organs were also assessed. Other surrogate parameters indicating disease severity, such as weight loss after BMT, presence of chronic diarrhea, performance status measured by KPS, and the presence of infectious complications, were also included for analysis.
Coding system of the clinical variables analyzed for prognostic factors for patients who developed cGVHD The most common sites of involvement were coded at the time of diagnosis of cGVHD into two or three grades by using a coding system based on the one by Akpek et al. 10 with several modifications. These codes were then entered into the database for analyses. The coding system or cutoff points of other variables are listed in Table 1 .
Data collection instrument and methods
Subject-, disease-, and transplant-related variables were collected on standardized forms provided by the NBMTG. Survival, relapse, and complication data in the database, including those for cGVHD, are revised annually. Informed consent is obtained from all patients when they are registered with the NBMTG. This study was approved by the board of directors of NBMTG.
Patients diagnosed with cGVHD were selected from the NBMTG database. Data collection forms were sent out for the collection of clinical and laboratory data at the time of diagnosis of cGVHD, at the initiation of primary therapy, and, if used, at the initiation of secondary therapy. Immunosuppressive therapy regimens and responses to primary and secondary therapy were reviewed. Data on survival and relapse were collected as of March 2003.
Statistical analyses
Cox regression model was used for both univariate and multivariate analyses of risk factors for extensive cGVHD. Factors found to be significant (Po0.05) in the univariate analysis were included in the multivariate analysis.
To identify the prognostic factors for patients who developed cGVHD, the major statistical end point was 'cGVHD-specific survival' from the time of diagnosis of cGVHD. Although the term 'cGVHD-specific survival' does not completely exclude all deaths without recurrent malignancy, we used this term in its traditional meaning of recurrence censored survival. 10, 15, 22 Death because of relapse of underlying hematological disorders was censored at the time of relapse. Cox regression model was used to analyze data for the identification of prognostic factors. All clinical factors and laboratory data were initially categorized as several numeric variables (see above), and subsequently binarized during univariate analyses. The cutoff points were chosen to make optimal use of information, with the proviso that smaller groups contain at least 20% of the patients. A forward stepwise method was applied for detecting sets of independent significant factors. In the previously reported studies of prognostic factor analyses of cGVHD, the statistical end point was either cGVHDspecific survival, 10, 15, 22 or overall survival. 11 Our analyses were therefore also performed with overall survival as the statistical end point.
Survival distributions were estimated with the method of Kaplan and Meier, and compared by means of the longrank test. Cumulative incidence of cGVHD was calculated by treating death without cGVHD or relapse as a competing risk for cGVHD. The proportional hazards regression model with cGVHD entered as a time-dependent covariate was used to determine the effect of cGVHD on relapse, non-relapse mortality, and overall survival. All statistical analyses were performed with STATA software version 8.0 (College Station, TX, USA).
Results
Patient characteristics and incidence of cGVHD
Patient characteristics and BMT information are summarized in Table 2 .
Of the 255 BMT recipients, 119 (47%) developed cGVHD. The cumulative incidence of cGVHD 2 years after transplant was 42% (95% confidence interval (CI), 35-48%) ( Figure 1a ). Cumulative incidence of clinical extensive cGVHD 2 years after transplant was 31% (95% CI, 25-37%).
Risk factors for developing cGVHD
Among the factors evaluated as risks for the development of clinical cGVHD, only the presence of prior grades 2-4 aGVHD was identified as significant by univariate analysis (Table 3) . When the same clinical characteristics were analyzed for clinical extensive cGVHD, univariate analysis showed two factors to be significant, unrelated donor type (hazard ratio (HR) ¼ 1.8; 95% CI, 1.2-2.7; P ¼ 0.008), and prior grades 2-4 aGVHD (HR ¼ 1.9; 95% CI, 1.2-3.0; P ¼ 0.005). Multivariate analysis demonstrated that the factors constituting independent risk factors for clinical extensive cGVHD were unrelated donor type (HR ¼ 1.6; 95% CI, 1.1-2.5; P ¼ 0.02), and prior grades 2-4 aGVHD (HR ¼ 1.8; 95% CI, 1.1-2.7; P ¼ 0.02).
Effect of cGVHD on relapse and mortality
The median follow-up of survivors was 4.1 years. The probability of overall survival 4 years after the transplant Chronic GVHD in Japan Y Atsuta et al was 60% (95% CI, 53-66%), and cumulative incidence of relapse after 2 years was 21% (95% CI, 16-27%).
The analysis of the effects of cGVHD as a timedependent covariate with adjustments for patient age, sex, disease status, and donor type showed no statistical significance for relapse (HR ¼ 0.70; 95% CI, 0.37-1. Characteristics and survival of patients who developed clinical cGVHD Detailed information at the time of diagnosis of cGVHD was available for 110 of the 119 patients who developed cGVHD. Their characteristics are shown in Table 4 , and their clinical manifestations and laboratory data at the time of diagnosis of cGVHD are given in Table 1 .
Follow-up of survivors after the diagnosis of cGVHD (median length: 4.2 years) showed that 69 (63%) of the 110 patients were alive at the time of data collection. The probability of cGVHD-specific survival and overall survival 4 years after the diagnosis of cGVHD was 79% (95% CI ¼ 70-86%) (Figure 1b ) and 65% (95% CI ¼ 55-74%), respectively. Of the 41 deaths, 16 (39%) were the result of relapse and 25 (61%) of other complications. The latter consisted of various infections (seven patients) and organ failures associated with cGVHD (12 patients). Detailed information on their cause of death is summarized in Table 5 . The patient who died of gastric cancer was censored from the analysis of cGVHD-specific survival when the disease was diagnosed. For the 80 patients with clinical extensive cGVHD, cGVHD-specific survival and overall survival 4 years after the diagnosis of cGVHD were 76% (95% CI ¼ 65-84%) and 62% (95% CI ¼ 50-71%), respectively.
Prognosis of patients with cGVHD
Univariate analysis showed that age of 36 or older (HR ¼ 2.6; 95% CI, 1.1-6.3), o4% eosinophils at the time of diagnosis of cGVHD (HR ¼ 3.5; 95% CI, 1.3-9.5), Karnofsky score of o80% (HR ¼ 5.8; 95% CI, 2.5-13.3), presence of infectious complication (HR ¼ 5.7; 95% CI, 2.5-13.1), and use of corticosteroids before initiating treatment for cGVHD (HR ¼ 3.9; 95% CI, 1.8-8.7) were significant prognostic factors (Table 4, Table 1 ). Corticosteroids were being administered to 23 patients (22%) at the onset of cGVHD. All patients received steroids for treatment of acute GVHD and were in the process of tapering off when the cGVHD developed. Multivariate analysis identified three factors at the time of diagnosis of cGVHD as independent predictors for non-relapse mortality: presence of infection (HR ¼ 4.1; 95% CI, 1.6-10.4), use of corticosteroids (HR ¼ 3.9; 95% CI, 1.7-9.1), and KPS o80% (HR ¼ 4.7; CI, 2.0-11.3) ( Table 6 ). These results enabled us to establish a prognostic model for cGVHD-specific survival or relapse-censored survival in terms of how many of these three risk factors are present. Figure 2 shows the probability of cGVHDspecific survival for patients divided into three risk groups according to this model. The estimated 4-year cGVHD-specific survival was 91.8% for patients without any prognostic factors (PFs) (n ¼ 51), 72.6% for those with one or two factors (n ¼ 42), and 14.3% for those with all three factors (n ¼ 7) (Po0.0001; log rank test). Six of the seven patients who showed all three prognostic factors died within 8 months after the diagnosis of cGVHD. The same three risk groups were used successfully for overall survival. The estimated 4-year overall survival was 80% for patients without any prognostic factors (PFs) (n ¼ 51), 60% for those with one or two factors (n ¼ 42), and 0% for those with all three factors (n ¼ 7) (Po0.0001; log rank test). Univariate and multivariate analyses confirmed the same three factors as independent prognostic factors when the subjects were limited to 80 patients with clinical extensive cGVHD. These three risk groups thus resulted in successful categorization of patients with clinical extensive cGVHD for prognosis of cGVHD-specific survival (Po0.0001; GVHD ¼ graft-versus-host disease.
Chronic GVHD in Japan Y Atsuta et al log rank test) as well as of overall survival (Po0.0001; log rank test).
Comparison with other grading systems
The classical grading system of limited/extensive-type cGVHD produced the survival curves in Figure 3a for our patients after the diagnosis of cGVHD. The result shows that the probability of cGVHD-specific survival 4 years after the diagnosis of cGVHD was 76% (95% CI, 65-84%) for the extensive type and 89% (95% CI, 70-96%) for the limited type, without any statistically significant difference (log rank test; P ¼ 0.34). There was no significant difference either when the statistical end point was overall survival (log rank test; P ¼ 0.25). In this case, the probability of overall survival 4 years after the diagnosis of cGVHD was 62% (95% CI, 50-72%) for the extensive type and 76% (95% CI, 56-88%) for the limited type. Another grading system by Akpek et al. 15 was also used. None of the factors used in this grading system, for example, progressive-type onset, extensive involvement of more than 50% of total skin surface area, and thrombocytopenia proved to be prognostic for our patients (Table 1) . Categorization according to this system for cGVHD-specific survival when matched to the system's statistical end point could not produce a useful stratification of our patients (Figure 3b) . Finally, the grading system by Lee et al. 11 was used for our patients for overall survival matched to that system's statistical end point. The results in Figure 3c show that the majority of patients were classified into the low or intermediate risk group, and only seven patients as high risk, with no statistically significant difference between the low-and intermediate-risk groups (log rank test; P ¼ 0.33). The results were quite similar when Akpek et al.'s and Lee et al.'s grading systems were applied to the 80 subjects with clinical extensive cGVHD. More than 90% of our patients were classified in the lower Figure 3 Survival curves after the diagnosis of cGVHD according to the classical limited/extensive grading system. cGVHD-specific survival at 4 years was 89% (95% CI, 70-96%) (n ¼ 30) and 76% (95% CI, 65-84%) (n ¼ 80), respectively (a). With Akpek's prognostic scoring (PS) system, the cGVHD-specific survival at 4 years was 79% (95% CI, 70-92%) (n ¼ 48) for PS ¼ 0, 84% (95% CI, 70-92%) (n ¼ 51) for 0oPSo1.9, and 46% (95% CI, 11-76%) (n ¼ 9) for 1.9oPS of cGVHD-specific survival at 4 years (b). With Lee's grading system, overall survival at 4 years was 73% (95% CI, 59-84%) (n ¼ 51) for low risk, 69% (95% CI, 53-81%) (n ¼ 42) for intermediate risk, and 29% (95% CI, 4-61%) (n ¼ 7) for high risk (c).
Low risk
risk groups with no significant difference between the two groups (log rank test; P ¼ 0.47 and 0.59, respectively).
Discussion
The aim of this study was to identify the incidence and risk factors of cGVHD, as well as the survival and prognostic factors for patients who developed cGVHD among Japanese BMT patients, who show a lower incidence and severity of acute GVHD than patients in Western countries. [17] [18] [19] 23 Our analyses concerning cGVHD showed that the incidence and risk factors of our study group were comparable to those of Western patients. The most important risk factor among various factors found to be associated with the development of cGVHD is the existence of prior acute GVHD. [2] [3] [4] [5] [6] [7] A recent report comparing GVHD and survival after HLA-identical sibling BMT in ethnic populations showed no differences in the risk for cGVHD. 23 The results of our analysis were consistent with those reported in the literature.
We also used recently reported prognostic scoring systems, which were developed on the basis of clinical findings for Western patients, on our Japanese patients, and unexpectedly found that these scoring systems did not produce an effective categorization. None of the three prognostic factors at the diagnosis of cGVHD in Akpek et al.'s scoring system were found to be prognostic in our analyses. When we compared the percentage of patients with Akpek et al.'s prognostic factors recorded in published data from Western countries with the corresponding percentages for our patients, we found some major differences. The proportion of progressive type onset of cGVHD is reportedly 20-70% in Western countries, 3, 11, 15 but was only 4% for our patients. The extent of cutaneous cGVHD was also different, with the incidence of those presenting with cutaneous lesions covering more than 50% of the total skin area was 9.5% for our patients, but 25-72% for those reported by Akpek et al. 15 These differences are likely to result in different results for prognostication and point to the need for the establishment of a different model for Japanese patients.
Our analyses identified the ongoing use of corticosteroids at the onset of cGVHD as a significant prognostic factor, which has not been included in previous studies. 10, 11, 14 Whether the use of a certain agent can be a prognostic factor is associated with how it is used. Approximately 20% of our patients were using corticosteroids at the time of diagnosis of cGVHD, and their steroid use was associated with prior acute GVHD. Wagner et al. 4 reported that 59% of patients were still under corticosteroid treatment on day 100, which was higher than for our series. They further showed that steroid use on day 100 was an adverse prognostic factor for patients after HSCT. Przepiorka et al. found that 40% of patients were on steroid treatment on day 100 and showed poorer prognosis, 5 but neither of these studies examined steroid use at the time of cGVHD onset. Because the occurrence of cGVHD despite the use of corticosteroids indicates resistance to immunosuppressive therapies and an immunodeficient status, it is reasonable to assume that steroid use at the diagnosis of cGVHD acts as an adverse prognostic factor. We believe therefore that the use of corticosteroids should be more widely examined for its prognostic significance.
The probability of cGVHD-specific survival of our patients was fairly high, 79% at 4 years, while the probability was o60% at 4 years in the study by Akpek et al. 10 A recent Korean study reported a cGVHD-specific survival of 74.2% at 5 years, which is similar to our result. 22 The presence of cGVHD did not show prognostic significance for our patients, which might be the result of the neutralization of the positive and negative effects of cGVHD on survival. The result of our analyses limited to those with clinical extensive cGVHD indicate that it is not due to the higher proportion of patients with limited cGVHD in Japanese patients which contribute to the different outcomes from the Westerns.
In conclusion, we identified three prognostic factors for patients who developed cGVHD. Since the manifestations of cGVHD in Japan are different from those in Western countries, the morbidity and mortality of cGVHD were found to be lower for Japanese patients. This indicated the need for a different prognostic model to identify high-risk patients.
